Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease non-alcoholic fatty liver disease
Symptom C2711227|steatohepatitis
Sentences 21
PubMedID- 26057287 Even though the ability to identify the nonalcoholic steatohepatitis subtype within those with nonalcoholic fatty liver disease still requires liver biopsy, biomarkers to detect advanced fibrosis are increasingly reliable.
PubMedID- 20689156 These findings are in line with recent studies showing that mir-34a is the most elevated mir in livers exhibiting nonalcoholic steatohepatitis, a spectrum of nonalcoholic fatty liver diseases in humans .
PubMedID- 24576046 Purpose: to determine whether gadoxetic acid-enhanced magnetic resonance (mr) imaging can be used to distinguish between simple steatosis and nonalcoholic steatohepatitis (nash) in patients with nonalcoholic fatty liver disease (nafld), defined according to the steatosis activity and fibrosis (saf) scoring system, which is based on the semiquantitative scoring of steatosis activity and liver fibrosis.
PubMedID- 24102757 Moreover, coffee consumption was inversely related to the severity of steatohepatitis in patients with non-alcoholic fatty liver disease.
PubMedID- 19932590 Non-alcoholic steatohepatitis (nash) is part of the spectrum of non-alcoholic fatty liver disease (nafld), which includes from simple steatosis and steatohepatitis, to the most severe cirrhosis and carcinoma, which develops in the absence of excessive alcohol intake.
PubMedID- 22521357 Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (nafld).
PubMedID- 25106814 Aim: to develop a non-invasive predictive model of non-alcoholic steatohepatitis in children with non-alcoholic fatty liver disease.
PubMedID- 23717739 Nonalcoholic steatohepatitis in nonalcoholic fatty liver disease patients of bangladesh.
PubMedID- 21145841 Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity.
PubMedID- 21725512 Predictive factors for nonalcoholic steatohepatitis (nash) in patients with nonalcoholic fatty liver disease (nafld).
PubMedID- 23576797 Metabolic syndrome is often accompanied by development of hepatic steatosis and less frequently by non-alcoholic fatty liver disease (nafld) leading to non-alcoholic steatohepatitis (nash).
PubMedID- 24598864 More importantly, obesity related metabolic disorders manifest in liver, causing liver steatosis, nonalcoholic fatty liver disease, eventually leading to inflammatory steatohepatitis 2.
PubMedID- 23851679 Nonalcoholic steatohepatitis (nash) is part of the spectrum of nonalcoholic fatty liver disease.
PubMedID- 22097893 Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease.
PubMedID- 24345846 A 4-polymorphism risk score predicts steatohepatitis in children with nonalcoholic fatty liver disease.
PubMedID- 21460032 Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using mr elastography.
PubMedID- 26215061 The development of a clinical score for the prediction of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease using routine parameters.
PubMedID- 22930399 Validation of terminal peptide of procollagen iii for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.
PubMedID- 24821109 Apoptosis is an early event of steatohepatitis in non-alcoholic fatty liver disease (nafld), and an increase in oxidative stress induced by hyperglycemia has been linked to an acceleration of apoptosis in hepatocytes.
PubMedID- 25801076 Background: the pnpla3/adiponutrin rs738409 c/g single nucleotide polymorphism is associated with the severity of steatosis, steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease, as well as the severity of steatosis and fibrosis in patients with chronic hepatitis c (chc).
PubMedID- 20336392 Background: a simple model to predict nonalcoholic steatohepatitis (nash) in patients with nonalcoholic fatty liver disease is desirable to optimize the selection of patients for liver biopsy.

Page: 1